Canaccord Genuity Maintains Buy on GeneDx Holdings, Lowers Price Target to $75
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $100 to $75.
Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $100 to $75.